|1.||Li, Jian: 46 articles (12/2015 - 05/2003)|
|2.||Nation, Roger L: 40 articles (12/2015 - 05/2003)|
|3.||Falagas, Matthew E: 22 articles (01/2014 - 01/2005)|
|4.||Michalopoulos, Argyris: 12 articles (05/2011 - 01/2005)|
|5.||Kasiakou, Sofia K: 10 articles (06/2006 - 01/2005)|
|6.||Giamarellou, Helen: 9 articles (12/2015 - 11/2002)|
|7.||Rolain, Jean-Marc: 9 articles (03/2015 - 01/2008)|
|8.||Falagas, M E: 9 articles (02/2014 - 02/2005)|
|9.||Couet, William: 8 articles (02/2015 - 08/2010)|
|10.||Turnidge, John D: 7 articles (12/2015 - 05/2003)|
08/01/2014 - "The purpose of this investigation was to compare the efficacy of colistin-based therapies in extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). "
03/01/2015 - "Based on the above assessments, the quality of evidence presented for each outcome ranged from "very low" to "low." A significant improvement in clinical response (odds ratio, 1.57; 95% CI, 1.14-2.15; p = 0.006; I2 = 37%), microbiological eradication (odds ratio, 1.61; 95% CI, 1.11-2.35; p = 0.01; I2 = 0%), and infection-related mortality (odds ratio, 0.58; 95% CI, 0.34-0.96; p = 0.04; I2 = 46%) was observed with the addition of aerosolized colistin to i.v. treatment, whereas the addition of aerosolized colistin did not affect overall mortality (odds ratio, 0.74; 95% CI, 0.54-1.01; p = 0.06; I2 = 25%) or nephrotoxicity (odds ratio, 1.18; 95% CI, 0.76-1.83; p = 0.45; I2 = 0%). "
10/01/2014 - "We report three cases of external ventricular derivation infections caused by multidrug-resistant Gram-negative rods and treated successfully with intraventricular colistin. "
06/01/2014 - "No statistically significant differences were observed between patients who achieved and failed to achieve bacterial cure with regards to age, gender, site of infection, mg/kg dose or duration of colistin use. "
12/01/2015 - "Colistin was substantially less effective in lung infection. "
12/01/2004 - "Successful therapy of carbapenem-resistant Acinetobacter baumannii strains has been reported with colistin, but recently we argued against its use as monotherapy because of the poor results obtained in a mouse pneumonia model. "
08/01/2003 - "Colistin did not lead to good results in a mouse pneumonia model. "
11/01/2010 - "In conclusion, inhaled colistin was effective and safe for the treatment of two children with tracheobronchitis, and one child with necrotizing pneumonia. "
01/01/2011 - "A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa."
09/01/2009 - ": To study the efficacy of intratracheal colistin sulfate therapy in a murine model of acute pneumonia caused by a clinical CRAB strain, Ab396. "
|3.||Ventilator-Associated Pneumonia (Pneumonia, Ventilator Associated)
12/01/2012 - "In this study we aimed to assess the safety and efficacy of high-dose IV colistin (COL) and aerosolized COL for the treatment of Acinetobacter baumannii ventilator-associated pneumonia (VAP). "
12/01/2012 - "Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii."
08/01/2007 - "Colistin-susceptible ventilator-associated pneumonia episodes can be effectively treated using colistin without significant renal dysfunction. "
03/01/2015 - "Based on the present results and awaiting further evidence from randomized trials, aerosolized colistin is associated with improved outcome in the treatment of ventilator-associated pneumonia although the level of evidence was low."
12/01/2012 - "The aim of the study was to assess efficacy of nebulized colistin for treating ventilator-associated pneumonia (VAP) caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. "
|4.||Critical Illness (Critically Ill)
12/01/2010 - "Although the pharmacodynamic parameters that better predict the efficacy of colistin are not known in humans, in critically ill adult patients the IV administration of CMS 2 million International Units (174 mg) q8h results in apparently suboptimal plasma concentrations of colistin, which is undetectable in BAL. "
08/01/2015 - "The present study has demonstrated that the addition of inhaled colistin to IV colistin led to a shorter TBE in critically ill children with VAP due to COS GNB. "
12/01/2014 - "In this study, CMS and colistin concentrations were measured on two separate occasions within the plasma and epithelial lining fluid (ELF) of critically ill patients (n = 12) who had received 2 million international units (MIU) of CMS by aerosol delivery and then intravenous administration. "
07/01/2014 - "Our study showed that high-dose, extended-interval colistin can be given to critically ill patients without any significant risk of nephrotoxicity."
08/01/2013 - "The objective was to study the PK/PD differences of CMS and colistin between three different CMS dosage regimens in the same critically ill patient. "
08/01/2015 - "Safety and Efficacy of Intravenous Colistin in Neonates With Culture Proven Sepsis."
08/01/2015 - "We present our experience of efficacy and safety of intravenous colistin in the treatment of sepsis in term and preterm neonates. "
03/01/2015 - "Antimicrobial therapy for sepsis caused by carbapenem- and colistin-resistant Klebsiella pneumoniae is not well established. "
01/01/2015 - "The significant variability of pharmacokinetic parameters of colistin was established both in patients with septicemia and in control group. "
12/01/2014 - "Efficacy and safety of intravenous colistin in preterm infants with nosocomial sepsis caused by Acinetobacter baumannii."
|3.||Anti-Bacterial Agents (Antibiotics)
|9.||Amphotericin B (Amphotericin)
|1.||Intensive Care (Surgical Intensive Care)
|2.||Artificial Respiration (Mechanical Ventilation)